Overview

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

Status:
Recruiting
Trial end date:
2024-06-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Iqvia Pty Ltd